



HAL
open science

Natural killer cells modulation in hematological malignancies

Céline T Baier, Aurore T Fino, Carole T Sanchez, Laure Farnault, Pascal Rihet, Brigitte T Kahn-Perlès, Régis T Costello

► **To cite this version:**

Céline T Baier, Aurore T Fino, Carole T Sanchez, Laure Farnault, Pascal Rihet, et al.. Natural killer cells modulation in hematological malignancies. *Frontiers in Immunology*, 2013, NK and lymphoid cell biology (4), pp.459. 10.3389/fimmu.2013.00459 . hal-01455668

HAL Id: hal-01455668

<https://amu.hal.science/hal-01455668>

Submitted on 3 Feb 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Natural killer cells modulation in hematological malignancies

Céline Baier^{1,2}, Aurore Fino^{1,2}, Carole Sanchez¹, Laure Farnault^{1,3}, Pascal Rihet^{1,2}, Brigitte Kahn-Perlès^{1,2} and Régis T. Costello^{1,2,3*}

¹ UMR1090 TAGC, INSERM, Marseille, France

² UMR1090 TAGC, Aix-Marseille Université, Marseille, France

³ Service d'hématologie, APHM, Hôpital de la Conception, Marseille, France

Edited by:

Massimo Vitale, IRCCS A.O.U.
S.Martino-IST, Italy

Reviewed by:

Laurel L. Lenz, National Jewish
Health, USA

Jacques Zimmer, Centre de
Recherche Public de la Santé,
Luxembourg

Nicolas Dulphy, Université Paris
Diderot, France

Renato Zambello, Padova University
School of Medicine, Italy

*Correspondence:

Régis T. Costello, Service
d'hématologie, APHM, Hôpital de la
Conception, 147 Bd Baille, 13005
Marseille 13005, France
e-mail: regis.costello@free.fr

Hematological malignancies (HM) treatment improved over the last years resulting in increased achievement of complete or partial remission, but unfortunately high relapse rates are still observed, due to remaining minimal residual disease. Therefore, sustainment of long-term remission is crucial, using either drug maintenance treatment or by boosting or prolonging an immune response. Immune system has a key role in tumor surveillance. Nonetheless, tumor-cells evade the specific T-lymphocyte mediated immune surveillance using many mechanisms but especially by the down-regulation of the expression of HLA class I antigens. In theory, these tumor-cells lacking normal expression of HLA class I molecules should be destroyed by natural killer (NK) cells, according to the missing-self hypothesis. NK cells, at the frontier of innate and adaptive immune system, have a central role in tumor-cells surveillance as demonstrated in the setting of allogeneic stem cell transplantation. Nevertheless, tumors develop various mechanisms to escape from NK innate immune pressure. Abnormal NK cytolytic functions have been described in many HM. We present here various mechanisms involved in the escape of HM from NK-cell surveillance, i.e., NK-cells quantitative and qualitative abnormalities.

Keywords: hematological malignancies, natural killer cells, natural cytotoxicity receptors, immune escape, immunotherapy

INTRODUCTION

The natural killer (NK) cells are central players in innate immunity particularly regarding the surveillance against malignant tumors (1, 2). NK role in tumor-cells clearance is proved by allogeneic stem cells transplantation, since a better engraftment and a low relapse rate are observed when the graft NK inhibitory receptors mismatch with recipient HLA molecules (3) (Figure 1). The triggering event of NK-cells activation and killing of target cells results from a balance between activating and inhibitory signals sent by membrane receptors that either enhance or block the NK-mediated cytotoxicity (4). Inhibitory signals arise from interaction between HLA-specific inhibitory receptors, as the killer immunoglobulin-like receptors (KIR), NK group protein 2A (NKG2A), or Immunoglobulin-like transcript 2 (ILT-2) with HLA class I molecules, whereas the absence or abnormal expression of the later molecules induces NK-cells cytotoxicity (5). The down-regulation of HLA class I molecules is an immune escape mechanism frequently used by tumor cells (6) that, accordingly, should not be recognized by the T-lymphocyte receptor (TCR). The absence of normal HLA class I molecule on tumor cells should lead to NK-cells activation, more efficiently when co-stimulatory molecules and ligands for NK activating receptor are present at tumor cell surface. The natural cytotoxicity receptors (NCR) NKp46/NCR1, NKp30/NCR3, and NKp44/NCR2 (7), NKG2D, DNAM-1 and also co-receptors such as 2B4/CD244 and NTBA, play a central role in NK activation. Once activated, NK lymphocytes kill tumor cells via FcγRIIIA (CD16) which can trigger


antibody-dependent cellular cytotoxicity (ADCC) on encountering target cells opsonized with IgG, via the Fas/Fas-L pathway and via cytotoxic granules (perforin/granzyme) secretion (1, 8).

Defects in NK-cell cytotoxicity have been described in most hematological malignancies (HM) (9–12) (Table 1). Interestingly, tumor-cells develop various escape mechanisms to NK-cell surveillance and contribute to the dysfunction of NK-cell cytotoxicity (4).

NK-CELLS DYSFUNCTIONS IN HEMATOLOGICAL MALIGNANCIES

QUANTITATIVE ABNORMALITIES

The first mechanism explaining tumor escape is the quantitative abnormalities of NK cells. In myelodysplastic syndrome (MDS) patients, decreased NK-cell cytolytic functions correlate with a low number of circulating NK cells and a high level of sIL-2R (13, 14). In chronic myelogenous leukemia (CML), functional NK-cell deficiency can be reversed *in vitro* by IL-2 (15), but this effect is progressively lost while a progressive decrease in NK-cell number is observed (16). In Philadelphia (Ph1)-negative myeloproliferative syndrome (MPS), NK cytotoxic activity is decreased, mostly in idiopathic myelofibrosis (IMF) patients. The percentage of NK cells is decreased in IMF and increased in polycythemia vera (PV) (17). We have confirmed that the percentage and absolute number of NK cells are significantly increased in PV, but we failed to detect any abnormalities in the expression of activating NK-cell receptors or cytotoxic functions (personal data, C. Sanchez). An



increase in the total number of NK cells in the peripheral blood has also been described in chronic lymphocytic leukemia (CLL) but still associated with defective cytolytic functions (18).

ALTERED ACTIVATING RECEPTORS PROFILES

In acute myeloid leukemia (AML) the down-regulation of activating receptors NKp30/NCR3 and NKp46/NCR1 correlates with defective NK-cell cytotoxicity and poor leukemia prognosis (9, 19). In patients attaining complete remission (CR) after chemotherapy, NKp46/NCR1 expression returns to normal levels while patients who do not achieve CR or who relapse maintain abnormal NCR expression (9, 19). The defect in NCRs expression could be potentiated by the low expression of NCR and NKG2D ligands by leukemic cells (20–22). Down-regulation of the NK activating receptors/co-receptor DNAM-1, 2B4/CD244, and CD94/NKG2C have also been reported in AML (23, 24). Leukemic blasts that express DNAM-1 ligands induce DNAM-1 down-regulation at the NK-cell surface (25), thus impeding NK-cell functions.

In acute lymphoblastic leukemia (ALL), expression of the NKG2D activating receptor ligands MICA/B was only observed in NK sensitive T-ALL cell line, while NK-resistant B-ALLs did not express detectable amounts of MICA/B (26). Deficient engagement of other activating receptors may also contribute to ALL resistance to NK lysis, since B-ALL cells lose or express low levels of several other NK activating ligands such as UL-16 binding proteins (ULBPs), PVR (polio virus receptor, CD155), Nectin-2 (CD112), or CD48 (27).

In MDS, a pre-leukemic stage, Epling-Brunette et al. (13) have shown that expression of NKp30/NCR3 and NKG2D was

decreased, in contrast with the data of Kiladjian et al. (28); this discrepancy could be related to the heterogeneity of MDS patients.

In CML patients, Boissel et al. (29) reported high serum sMICA levels and weak NKG2D expression on NK cells, that correlate with low NK-cell cytotoxicity capacities. Imatinib mesylate, the first inhibitor of tyrosine kinase used in CML, increases NKG2D expression and decreases MICA protein production and release, thus contributing to normal NK cytotoxicity through the restoration of a functional NKG2D signaling (29).

Monoclonal gammopathy of undetermined significance (MGUS) is a common disorder of aging and a precursor lesion to multiple myeloma (MM). In MGUS, tumor-cells express high levels of MICA, whereas low levels of sMICA are detected in peripheral blood (30). This explains the capacities of NK cells to kill MGUS tumor cells by interaction between MICA and NKG2D. Conversely, MM patients present high plasma level of sMICA while tumor-cells express low level of MICA, thus impeding NK stimulation via NKG2D (31). This reveals that the alterations in the NKG2D pathway signaling are associated with the progression from MGUS to MM (30, 32). In peripheral blood from patients with MM a normal expression of the NCRs and NKG2D is observed, while 2B4/CD244 and the low-affinity Ig-Fc receptor CD16 display significantly weaker expression in comparison with healthy donors (31). Nonetheless, when NK are studied at the site of tumor location, i.e., bone marrow, (33) a drastic down-regulation of three major activating NK receptors (NKp30/NCR3, NKG2D, and 2B4/CD244) is observed in comparison with bone marrow from healthy donors (34). This suggests that some NK abnormalities may be underestimated if only peripheral blood is studied.

Table 1 | Mechanisms of immune escape and drugs used with their effects on NK cells in hematological malignancies.

Hematological malignancies	Principal mechanisms of escape	References	Principal class of drugs used	Effects of drugs on NK activation	References
MDS	NK-cell quantitative deficiency Elevated TNF	(13, 14, 49)	Demethylating agents IMiDs	Up-regulation of KIR and NKG2D ligands NKp46 upregulation	(76, 81)
AML	Upregulation of HLA-I Decrease expression of NKp30, 2B4/CD244 Production of ROS	(9, 19, 39, 40, 54)	HDACIs Histamine dihydrochloride All-trans retinoic acid Monoclonal antibody (IPH2101)	Upregulation of MICA/B expression Suppress ROS production Promote NK-cells cytotoxicity	(65, 67, 72, 73, 84, 85)
CLL	Upregulation of HLA-I low level of MICA or ULBP	(18, 37)	Monoclonal antibody	Mediate NK-cells cytotoxicity	(88)
MM	Production of sMICA/sMICB Weak expression of CD16	(30, 31)	IMiDs Proteasome inhibitor IPH2101	NKp46 upregulation NKG2D ligand upregulation	(79, 82–84, 86)
CML	Production of sMICA and weak expression of NKG2D	(29)	Tyrosine kinase inhibitor	sMICA down-regulation and NKG2D upregulation	(29)
ALL	Low production of MICA/B and ULBP Down regulation of HLA-A and HLA-Bw6	(26, 27, 41)			

MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; s/MICA/B, soluble/stress-induced molecules human class I-like molecules A and B; ULBPs, UL-16 binding proteins; ROS, reactive oxygen species; KIR, killer immunoglobulin-like receptors; PDGF, platelet-derived growth factor; HDC, histamine dihydrochloride; IMiDs, immune-modulatory drugs; HDACIs, Histone deacetylase inhibitors.

In CLL, NK cells have weak cytotoxic functions which can be restored by stimulation with recombinant IFN- γ or IL-2 (35). We failed to detect a difference in NCR expression between patients and age-matched healthy donors (36), but we found a correlation with abnormal activating molecule expression and poor prognosis factors. In CLL decreased NK functions could be explained in part by absent or low level of MICA or ULBP (18, 37) at CLL lymphocyte cell surface, thus impeding NKG2D engagement.

ABNORMAL KIRs PHENOTYPE AND INHIBITORY MOLECULES

Killer immunoglobulin-like receptor-mismatch in allogenic stem cells transplantation improves the disease-free survival in AML (38). In fact, NK-cell cytotoxicity is down-regulated by the engagement of HLA-specific inhibitory receptors, including KIRs and CD94 and NKG2A/B heterodimers. The analysis of KIR phenotype in AML patients shows that the frequency of particular inhibitory KIRs in association with their putative HLA class I ligands is significantly increased compared to healthy donors (10, 39, 40). This supports the hypothesis that AML blasts escape from immune surveillance according to the dominance of inhibitory over activating KIR signals. In ALL, the resistance of B-cell precursors to cytotoxicity is explained by the interaction between HLA-G and KIR2DL4 (26). Demanet et al. (41) have observed in ALL and CLL a selective down-regulation of HLA-A and HLA-Bw6 associated with HLA-Bw4 preservation, which provided an escape mechanism from NK-cell immune surveillance. Maki et al. (18) reported

in CLL cells an increased expression of HLA-G1, a class I molecule that engages NK-cell inhibitory molecules and which has for ligand and p49/KIR2DL4/CD158d (expressed on NK cells and a fraction of T cells), ILT-2 [expressed on NK, T, B cells, dendritic cells (DC), and monocytes], and ILT-4 [expressed on antigen-presenting cells (APC)] (42).

TUMOR ENVIRONMENT AND ROLE OF CYTOKINES

One of the strategies used by tumor cells having an effect on NK-cell function is the production of inhibitory molecules, which decrease NK-cells number and inhibit NK-cell activation. Increasing evidence supports the role of the tumor microenvironment in conferring drug resistance, a major cause of relapse and incurability of cancers. Tumor microenvironment includes tumor-cells contact and interaction, but also production of soluble factors, which provide signals for tumor growth and survival or inhibition of NK.

ROLE OF CYTOKINES AND CELLULAR LIGANDS

Several cytokines decrease NK-cell activation and cytotoxicity, such as the Transforming Growth Factor beta (TGF- β). High circulating TGF- β level correlates with poor prognosis in acute leukemia (43) and is linked to reduced NK-cell activity with reduced expression of NKp30/NCR3 and NKG2D (44). TGF- β antagonizes IL-15, a cytokine that induces NK-cell proliferation and activation. Thus, TGF- β inhibits the expression of both NK-cell activation

receptor molecules and components of the cytotoxic apparatus (45, 46). Several studies have also underlined that low INF- γ producing capacity of NK cells was correlated with loss of NK-cell cytotoxicity (47, 48).

A physiologic concentration of platelet-derived growth factor (PDGF) significantly inhibits human NK-cell cytotoxicity. Patients suffering from IMF and essential thrombocythemia have significantly elevated circulating levels of plasma PDGF. Pretreatment of normal NK cells with concentrated PDGF-containing platelet-poor plasma from patients with these diseases significantly inhibits NK cytotoxicity. This inhibitory effect is reversed by neutralization of plasma PDGF with anti-PDGF (17, 49). All these data suggest that PDGF is probably a key factor of NK functional deficiency in MPS.

Interaction between tumor cells and NK impairs NK-cell-mediated cytotoxicity and thus induces tolerance to tumor invasion. Up-regulation of the immunosuppressive cell surface glycoprotein CD200 and of soluble GITRL (glucocorticoid-induced TNFR related protein ligand) on AML cells specifically compromises NK-cell anti-tumor responses (50, 51) and is a poor prognosis factor. AML cells exert direct immunosuppressive effects on NK cells mediated by immunosuppressive ligands or soluble factors and induce regulatory T lymphocytes (Treg) that weaken NK-cell responses (52). NK cells can also interact with DC leading to activation of Treg and inhibition of NK cells (53). Recently, ligand of NKp44/NCR2 (NKp44L) was identified as an isoform of mixed-lineage leukemia-5 (MLL5) (54). This ligand is not detectable in the normal tissues but is present in hematopoietic, non-hematopoietic tumor and transformed cells. The expression of MLL5 is a good prognosis factor in AML (55). Thus we can speculate that the prognostic value of MLL5 expression is linked to its capacity to activate anti-leukemia NK cells.

REACTIVE OXYGEN SPECIES

Non-malignant phagocytic cells down-modulate lymphocyte functions by producing and releasing NADPH oxidase-derived reactive oxygen species (ROS) (56). Monocytic and myelomonocytic (French-American-British classification M4/M5 subtypes) AML cells, but not cells from myeloblastic (FAB class M2) or immature (FAB class M1) AML, produce ROS via the NADPH oxidase component gp91phox, and trigger extensive apoptosis of NK cells *via* a poly-[ADPribose] polymerase-1 dependent pathway, together with a down-regulation of NKp46/NCR1. This suggests a novel mechanism of immune evasion in myelo-monocytic and monocytic AML (57).

MATERIAL TRANSFER DURING CELL-CELL CONTACT

Tumor membrane-derived microvesicles (tMV) are important mediators of cell-to-cell communication. These circular membrane fragments are enriched in various bioactive molecules and directly stimulate cells as a kind of "signaling complex." An important mode of communication between carcinoma cells and immune cells involves tMV, also known as exosomes, ectosomes, or microparticles. These microvesicles carry lipids, proteins, mRNAs, and microRNAs and travel short or long distances to deliver undegraded and undiluted material to other cells (58). Microvesicles

present in AML patients' sera contain TGF- β that down-regulates the expression of NKG2D and thus interfere with NK-cell activation. Nonetheless, IL-15 protects NK cells from adverse effects of tMV and could thus contribute to maintain their anti-tumor response (59). Baj-Krzyworzeka et al. (60) have observed that tMV carry mRNA of tumor cells and transfer some of them to monocytes and modify their activity. This type of mRNA transfer could participate to NK inactivation and tumor escape to innate immunity.

IMMUNOTHERAPY APPROACHES

Modulation of NK-cell function by down-regulation of receptors and/or ligand corresponds to an immune escape mechanism for tumors. Restoring the expression of activating receptors on NK cells, or corresponding ligands on cancer cells, is an effective approach to cancer immunotherapy in order to improve disease-free survival after therapy. Currently, in most AML patients, the induction treatment leads to CR, defined as microscopic disappearance of leukemic disease along with the return of normal hematopoiesis. However, many patients in CR relapse with poor prospects of long-term survival. One of developing immunotherapy that enhances NK-cell ability to kill tumor cells is the allogeneic transplantation after chemotherapy. In AML, a recipient of haploidentical allogeneic transplant with a NK HLA-specific receptor-mismatch is associated with a favorable prognosis because this increases the anti-leukemic graft reactivity (61, 62). Rapid recovery of NK cells after hematopoietic stem cell transplantation has been associated with a reduction in the rates of relapse and acute graft-versus-host disease (GvHD) (63). The transfer of NK cell from haploidentical origins into AML recipients is a potent immunotherapy intervention that is, unfortunately, associated with a significant transplant-related morbidity and mortality that limit its use (64).

The use of cytokines is another therapeutic approach to enhance NK-cell cytotoxicity. IL-2, IL-12, IL-15 (65), and IL-18 have been used in culture to increase cell cytotoxic prior to the injection of NK cells in cancer patients (66). Another strategy consists in restoring normal NCR expression since these molecules are pivotal for the anti-leukemia response. A phase III study in 320 AML patients has demonstrated that immunotherapy with histamine dihydrochloride (HDC) and IL-2 decreases and delays relapses in AML (67). HDC suppresses or inhibits ROS formation in mononuclear and polymorphonuclear myeloid cells. This prevents from oxygen radical-induced NK apoptosis, restores NK-cell capacity to respond to IL-2, and improves NK proliferation and production of immuno-stimulatory cytokines (56, 68–71). Moreover, in presence of HDC, cytotoxic functions of NK cells remain intact due to the preserved expression of the activating receptors NKG2D and NKp46/NCR1.

DNA methylation also has a key role in the control of gene activity in cancer cells. Two agents are currently used in MDS treatment: 5-azacytidine (Vidaza) and 5-aza-20-deoxycytidine (Decitabine) (72). These two hypomethylating agents up-regulate NKG2D ligands MICA/B leading to enhanced NK-cell cytotoxicity (73, 74). Conversely we have observed the down-regulation of 2B4/CD244 in NK from AML patients treated with 5-azacytidine, that could

have an opposite effect, i.e., cytotoxicity down-regulation (Leclercq et al. personal data).

The immune-modulatory drugs (IMiDs) such as thalidomide and lenalidomide are used in MM and MDS treatment and have anti-angiogenic and anti-inflammatory properties. They also act as IMiDs by cytokine release and activating effector cells by enhancing ADCC and NK-cell cytotoxicity thanks to the up-regulation of Nkp46/NCR1 (75–77).

Bortezomib is a proteasome inhibitor used in MM treatment. Physiologically, proteasome is involved in protein degradation. Its inhibition by the drug interferes with tumor growth and with innate immunity. Bortezomib is involved in the down-regulation of HLA I molecules and in the up-regulation of NKG2D, TRAIL, and DNAM ligands, thus leading to increased NK-cell cytotoxicity against plasma cell (78, 79).

Another attractive therapeutic approach consists in blocking the NK inhibitory receptors. A phase I trial has tested the IPH2101, a fully humanized IgG4 anti-KIR monoclonal antibody, in patients with relapsed/refractory AML (clinical trial registration number NCT01256073) and MM (clinical trial registration number NCT00999830). IPH2101 promotes immune complex formation and NK-cell cytotoxicity specifically against MM cell targets but not normal cells. No evidence of autoimmunity was observed. These findings suggest that IPH2101 is safe and tolerable and that this approach warrants further development in MM and AML (80–82) as we are waiting for clinical results.

Several studies revealed ADCC as one major mode of action of antibody-based therapeutics and stimulated more interest in how to mobilize, expand, and activate NK cells in humans (83). In CLL, the ADCC pathway via the Fc receptor (FcγRIIIa) CD16 at surface of NK cells is pivotal in the clinical effect of mAbs such as rituximab or ofatumumab which mediate ADCC by NK cells (84). Second generation mAb are designed in order to maximize both direct apoptosis and ADCC. The role of ADCC is underlined by better clinical responses to rituximab when NK cells expressed the high-affinity form of the FcγRIII (85, 86).

Bi-specific NK-cell engagers (BiKE) simultaneously bind CD16α and c-Met (a receptor overexpressed in many tumors) and thus may increase NK-cell ADCC (87).

Another type of therapeutic strategy consists in taking advantage from anti-cancer drugs properties (Table 1). Chemotherapy drugs can be separated by their ability to inhibit (such as vinblastine, chlorambucil, docetaxel) or enhance (such as asparaginase, bleomycin, doxorubicin) NK-cell-mediated killing of target cells (88, 89). In cancer, epigenetic changes are also involved in dysregulating NK-cell ligand expression. Histone deacetylase inhibitors (HDACIs) such as trichostatin, are epigenetic anti-cancer agents that modulate innate immunity by the regulation of expression of NKG2D or DNAM-1 ligands. Indeed, HDACIs increase expression of ligands of these two activating receptors, MICA/B or PVR and Nectin-2 respectively, on acute leukemia cells (90, 91). This suggests that epigenetic drugs make tumor cells more sensitive to NK-cell-mediated lysis (92). However, it has also been demonstrated that HDACIs suppress NK-cell cytotoxic activity by down-regulation of Nkp30/NCR3, Nkp46/NCR1 (93). Thus, the same drug can have contradictory effects on NK cells.

CONCLUDING REMARKS

The more precise and exhaustive analysis of NK dysfunction in HM has opened the way to novel therapeutic strategies involving either specifically developed drugs/antibodies or innovative use of “old” drugs such as IMiDs. Due to the complexity of the immune response and the putative opposed effects of a drug on the various partners of the immune network, data obtained by *in vitro* experiments or *in vivo* in animal models have to be evaluated in clinically and biologically carefully monitored clinical trials.

ACKNOWLEDGMENTS

This work was supported by Grants from INSERM and Region Provence-Alpes-Côtes d’Azur “Bourse Doctorale Regionale 2011–2014.”

REFERENCES

- Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. *Nat Immunol* (2008) **9**:503–10. doi:10.1038/ni1582
- Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. *Science* (2011) **331**:44–9. doi:10.1126/science.1198687
- Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. *Blood Cells Mol Dis* (2008) **40**:84–90. doi:10.1016/j.bcmd.2007.06.029
- Costello RT, Gastaut JA, Olive D. Tumor escape from immune surveillance. *Arch Immunol Ther Exp (Warsz)* (1999) **47**:83–8.
- Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. *Immunol Today* (1990) **11**:237–44. doi:10.1016/0167-5699(90)90097-5
- Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. *Adv Cancer Res* (1995) **67**:155–95.
- Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytotoxicity. *Immunol Today* (2000) **21**:228–34. doi:10.1016/S0167-5699(00)01596-6
- Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. *J Allergy Clin Immunol* (2013) **132**:536–44. doi:10.1016/j.jaci.2013.07.006
- Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Revirion D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. *Blood* (2002) **99**:3661–7. doi:10.1182/blood.V99.10.3661
- Sanchez CJ, Le Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D, et al. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. *Cancer Immunol Immunother* (2011) **60**:1–13. doi:10.1007/s00262-010-0898-x
- Costello RT, Fauriat C, Sivori S, Marcenaro E, Olive D. NK cells: innate immunity against hematological malignancies? *Trends Immunol* (2004) **25**:328–33. doi:10.1016/j.it.2004.04.005
- Rey J, Veuillen C, Vey N, Bouabdallah R, Olive D. Natural killer and gammadelta T cells in hematological malignancies: enhancing the immune effectors. *Trends Mol Med* (2009) **15**:275–84. doi:10.1016/j.molmed.2009.04.005
- Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. *Blood* (2007) **109**:4816–24. doi:10.1182/blood-2006-07-035519
- Yokose N, Ogata K, Ito T, An E, Tamura H, Dan K, et al. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes. *Leuk Res* (1994) **18**:777–82. doi:10.1016/0145-2126(94)90060-4
- Chang WC, Fujimiyama Y, Casteel N, Pattengale P. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells. *Int J Cancer* (1989) **43**:591–7. doi:10.1002/ijc.2910430410
- Pierson BA, Miller JS. CD56+ bright and CD56+ dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number,

- respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. *Blood* (1996) **88**:2279–87.
17. Gersuk GM, Carmel R, Pattamakom S, Challita PM, Rabinowitz AP, Pattengale PK. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity. *Nat Immun* (1993) **12**:136–51.
 18. Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. *Leukemia* (2008) **22**:998–1006. doi:10.1038/leu.2008.15
 19. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. *Blood* (2007) **109**:323–30. doi:10.1182/blood-2005-08-027979
 20. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. *Eur J Immunol* (2001) **31**:1076–86. doi:10.1002/1521-4141(200104)31:4<1076::AID-IMMU1076>3.0.CO;2-Y
 21. Biassoni R, Cantoni C, Marras D, Giron-Michel J, Falco M, Moretta L, et al. Human natural killer cell receptors: insights into their molecular function and structure. *J Cell Mol Med* (2003) **7**:376–87. doi:10.1111/j.1582-4934.2003.tb00240.x
 22. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. *J Immunol* (2012) **189**:1360–71. doi:10.4049/jimmunol.1200796
 23. Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. *Cancer Immunol Immunother* (2011) **60**:1195–205. doi:10.1007/s00262-011-1050-2
 24. Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. *Leukemia* (2012) **26**:2019–26. doi:10.1038/leu.2012.87
 25. Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. *Immunol Cell Biol* (2012) **90**:109–15. doi:10.1038/icb.2011.15
 26. Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, et al. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. *Exp Hematol* (2005) **33**:344–52. doi:10.1016/j.exphem.2004.11.006
 27. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, Dondero A, et al. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. *Blood* (2006) **107**:2030–6. doi:10.1182/blood-2005-07-2696
 28. Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. *Leukemia* (2006) **20**:463–70. doi:10.1038/sj.leu.2404080
 29. Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. *J Immunol* (2006) **176**:5108–16.
 30. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. *Proc Natl Acad Sci U S A* (2008) **105**:1285–90. doi:10.1073/pnas.0711293105
 31. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. *Blood* (2005) **105**:251–8. doi:10.1182/blood-2004-04-1422
 32. Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. *Leukemia* (2006) **20**:732–3. doi:10.1038/sj.leu.2404096
 33. Costello RT, Boehrer A, Sanchez C, Mercier D, Baier C, Le Treut T, et al. Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. *Immunology* (2013) **139**:338–41. doi:10.1111/imm.12082
 34. Eissens DN, Spanholtz J, van der Meer A, van Cranenbroek B, Dolstra H, Kwekkeboom J, et al. Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. *PLoS One* (2012) **7**:e30930. doi:10.1371/journal.pone.0030930
 35. Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos GD. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. *Acta Haematol* (1996) **96**:16–23. doi:10.1159/000203709
 36. Costello RT, Knoblauch B, Sanchez C, Mercier D, Le Treut T, Sebahoun G. Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. *Immunology* (2012) **135**:151–7. doi:10.1111/j.1365-2567.2011.03521.x
 37. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). *Blood* (2005) **105**:2066–73. doi:10.1182/blood-2004-09-3548
 38. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science* (2002) **295**:2097–100. doi:10.1126/science.1068440
 39. Wetzler M, Baer MR, Stewart SJ, Donohue K, Ford L, Stewart CC, et al. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. *Leukemia* (2001) **15**:128–33. doi:10.1038/sj.leu.2401982
 40. Verheyden S, Demanet C. Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions. *Leukemia* (2006) **20**:1437–8. doi:10.1038/sj.leu.2404279
 41. Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? *Blood* (2004) **103**:3122–30. doi:10.1182/blood-2003-07-2500
 42. Creput C, Durrbach A, Charpentier B, Carosella ED, Rouas-Freiss N. [HLA-G: immunoregulatory molecule involved in allograft acceptance]. *Nephrologie* (2003) **24**:451–6.
 43. Bergmann L, Schui DK, Brieger J, Weidmann E, Mitrou PS, Hoelzer D. The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by transforming growth factor-beta 1. *Exp Hematol* (1995) **23**:1574–80.
 44. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. *J Immunol* (2004) **172**:7335–40.
 45. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. *Nat Rev Immunol* (2010) **10**:554–67. doi:10.1038/nri2808
 46. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, et al. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. *PLoS One* (2011) **6**:e22842. doi:10.1371/journal.pone.0022842
 47. Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. *Leukemia* (1996) **10**:478–82.
 48. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. *Proc Natl Acad Sci U S A* (2003) **100**:4120–5. doi:10.1073/pnas.0730640100
 49. Verhoeve GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. *Leukemia* (1992) **6**:1268–72.
 50. Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A, et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. *Leukemia* (2011) **25**:792–9. doi:10.1038/leu.2011.1
 51. Baessler T, Krusch M, Schmiedel BJ, Kloss M, Baltz KM, Wacker A, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. *Cancer Res* (2009) **69**:1037–45. doi:10.1158/0008-5472.CAN-08-2650

52. Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? *Blood* (2011) **118**:5084–95. doi:10.1182/blood-2011-07-365817
53. Fauriat C, Moretta A, Olive D, Costello RT. Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. *Blood* (2005) **106**:2186–8. doi:10.1182/blood-2005-03-1270
54. Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debre P, Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. *Blood* (2013) **122**:2935–42. doi:10.1182/blood-2013-03-489054
55. Damm F, Oberacker T, Thol F, Surdzien E, Wagner K, Chaturvedi A, et al. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. *J Clin Oncol* (2011) **29**:682–9. doi:10.1200/JCO.2010.31.1118
56. Thoren FB, Romero AI, Hellstrand K. Oxygen radicals induce poly(ADP-ribose) polymerase-dependent cell death in cytotoxic lymphocytes. *J Immunol* (2006) **176**:7301–7.
57. Aurelius J, Thoren FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, et al. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis. *Blood* (2012) **119**:5832–7. doi:10.1182/blood-2011-11-391722
58. Pucci F, Pittet MJ. Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. *Clin Cancer Res* (2013) **19**:2598–604. doi:10.1158/1078-0432.CCR-12-0962
59. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. *Haematologica* (2011) **96**:1302–9. doi:10.3324/haematol.2010.039743
60. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Zembala M. Tumour-derived microvesicles modulate biological activity of human monocytes. *Immunol Lett* (2007) **113**:76–82. doi:10.1016/j.imlet.2007.07.014
61. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. *Blood* (2007) **110**:433–40. doi:10.1182/blood-2006-07-038687
62. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. *Immunol Rev* (2006) **214**:202–18. doi:10.1111/j.1600-065X.2006.00455.x
63. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. *Leukemia* (2007) **21**:2145–52. doi:10.1038/sj.leu.2404892
64. Miller JS, Soignier Y, Panoskalis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood* (2005) **105**:3051–7. doi:10.1182/blood-2004-07-2974
65. Suck G, Oei VY, Linn YC, Ho SH, Chu S, Choong A, et al. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. *Exp Hematol* (2011) **39**:904–14. doi:10.1016/j.exphem.2011.06.003
66. Chan CJ, Andrews DM, Smyth MJ. Can NK cells be a therapeutic target in human cancer? *Eur J Immunol* (2008) **38**:2964–8. doi:10.1002/eji.200838764
67. Brune M, Castaigne S, Catalano J, Gehlens K, Ho AD, Hofmann WK, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. *Blood* (2006) **108**:88–96. doi:10.1182/blood-2005-10-4073
68. Hansson M, Hermodsson S, Brune M, Mellqvist UH, Naredi P, Betten A, et al. Histamine protects T cells and natural killer cells against oxidative stress. *J Interferon Cytokine Res* (1999) **19**:1135–44. doi:10.1089/107999099313073
69. Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell-mediated resistance against tumor cells. *J Immunol* (1990) **145**:4365–70.
70. Hellstrand K, Hermodsson S. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. *Int Arch Allergy Appl Immunol* (1990) **92**:379–89. doi:10.1159/000235169
71. Romero AI, Thoren FB, Brune M, Hellstrand K. NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. *Br J Haematol* (2006) **132**:91–8. doi:10.1111/j.1365-2141.2005.05842.x
72. Kopp LM, Ray A, Denman CJ, Senyukov VS, Somanchi SS, Zhu S, et al. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. *Mol Immunol* (2013) **54**:296–301. doi:10.1016/j.molimm.2012.12.012
73. Tang KF, He CX, Zeng GL, Wu J, Song GB, Shi YS, et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. *Biochem Biophys Res Commun* (2008) **370**:578–83. doi:10.1016/j.bbrc.2008.03.131
74. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, Wernet P, et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. *J Immunol* (2002) **169**:4253–61.
75. Davies FE, Raju N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. *Blood* (2001) **98**:210–6. doi:10.1182/blood.V98.1.210
76. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. *Br J Haematol* (2008) **140**:36–45.
77. Berg SL, Cairo MS, Russell H, Ayello J, Ingle AM, Lau H, et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. *J Clin Oncol* (2011) **29**:316–23. doi:10.1200/JCO.2010.30.8387
78. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. *Blood* (2008) **111**:1309–17. doi:10.1182/blood-2007-03-078535
79. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Galleonardo V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. *Blood* (2009) **113**:3503–11. doi:10.1182/blood-2008-08-173914
80. Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. *Curr Opin Mol Ther* (2010) **12**:724–33.
81. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, et al. A phase I trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. *Blood* (2012) **120**:4317–23. doi:10.1182/blood-2012-06-437558
82. Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. *Blood* (2012) **120**:4324–33. doi:10.1182/blood-2012-06-438028
83. Wallace ME, Smyth MJ. The role of natural killer cells in tumor control – effectors and regulators of adaptive immunity. *Springer Semin Immunopathol* (2005) **27**:49–64. doi:10.1007/s00281-004-0195-x
84. Weitzman J, Betancur M, Boissel L, Rabinowitz AP, Klein A, Klingemann H. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. *Leuk Lymphoma* (2009) **50**:1361–8. doi:10.1080/10428190903026500
85. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. *Blood* (2002) **99**:754–8. doi:10.1182/blood.V99.3.754
86. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, et al. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. *J Clin Oncol* (2005) **23**:474–81. doi:10.1200/JCO.2005.06.059
87. Boltz A, Piater B, Toleikis L, Guenther R, Kolmar H, Hock B. Bi-specific aptamers mediating tumor cell lysis. *J Biol Chem* (2011) **286**:21896–905. doi:10.1074/jbc.M111.238261
88. Markasz L, Skribek H, Uhlin M, Otvos R, Flaberg E, Eksborg S, et al. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. *J Immunother* (2008) **31**:283–93. doi:10.1097/CJI.0b013e3181628b76
89. Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud O. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in

- leukemogenesis and therapeutic implications. *Curr Top Microbiol Immunol* (2010) **341**:149–72. doi:10.1007/82_2010_25
90. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. *Leukemia* (2007) **21**:2103–8. doi:10.1038/sj.leu.2404862
91. Schmutte M, Braun A, Pende D, Sonnemann J, Klier U, Beck JF, et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. *Cancer Lett* (2008) **272**:110–21. doi:10.1016/j.canlet.2008.06.027
92. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. *Blood* (2008) **111**:1428–36. doi:10.1182/blood-2007-07-101311
93. Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl J Jr. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. *FEBS Lett* (2007) **581**:1317–22. doi:10.1016/j.febslet.2007.02.045

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 20 September 2013; accepted: 02 December 2013; published online: 19 December 2013.

Citation: Baier C, Fino A, Sanchez C, Farnault L, Rihet P, Kahn-Perlès B and Costello RT (2013) Natural killer cells modulation in hematological malignancies. *Front. Immunol.* **4**:459. doi: 10.3389/fimmu.2013.00459

This article was submitted to *NK Cell Biology*, a section of the journal *Frontiers in Immunology*.

Copyright © 2013 Baier, Fino, Sanchez, Farnault, Rihet, Kahn-Perlès and Costello. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.